PMID- 12183645
OWN - NLM
STAT- MEDLINE
DCOM- 20020918
LR  - 20190607
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 302
IP  - 3
DP  - 2002 Sep
TI  - Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge 
      administration of Ecstasy.
PG  - 898-907
AB  - The recreational use of 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) is 
      often characterized by a repeated pattern of frequent drug administrations 
      (binge) followed by a period of abstinence. Radiotelemetry was used to 
      characterize the cardiovascular responses elicited during three MDMA binges (3 or 
      9 mg/kg b.i.d. for 4 days), each of which was separated by a 10-day MDMA-free 
      period. The heart rate and mean arterial pressure (MAP) responses elicited by 
      3-mg/kg doses of MDMA were consistent within and between the three binges. In the 
      first binge the 9-mg/kg doses of MDMA increased MAP and produced a biphasic 
      (decrease/increase) heart rate response. The bradycardia elicited by MDMA in the 
      first binge (-75 bpm) was enhanced in the second and third binges (-186 and -287 
      bpm, respectively). Significant hypotension accompanied the increased bradycardic 
      responses. Atropine abolished the hypotension and significantly attenuated the 
      bradycardic responses. The MAP and heart rate responses elicited by sodium 
      nitroprusside, acetylcholine, phenylephrine, and serotonin (5-HT) were evaluated 
      before each binge and 10 days after the last binge. The hypotension, but not the 
      tachycardia elicited by sodium nitroprusside was attenuated by the repeated 
      administration of MDMA. The responses to phenylephrine, acetylcholine, and 5-HT 
      were unaltered after MDMA. The hearts of treated rats contained foci of 
      inflammatory infiltrates (lymphocytes and macrophages), some of which contained 
      necrotic cells and/or disrupted cytoarchitecture. MDMA produced cardiac 
      arrhythmias in some rats. These results indicate that the binge administration of 
      MDMA can significantly alter cardiovascular and cardiovascular reflex function 
      and produce cardiac toxicity.
FAU - Badon, Lisa A
AU  - Badon LA
AD  - Loyola University New Orleans, Tulane School of Medicine, New Orleans, Louisiana, 
      USA.
FAU - Hicks, Alissa
AU  - Hicks A
FAU - Lord, Kevin
AU  - Lord K
FAU - Ogden, Brian A
AU  - Ogden BA
FAU - Meleg-Smith, Suzanne
AU  - Meleg-Smith S
FAU - Varner, Kurt J
AU  - Varner KJ
LA  - eng
GR  - DA-08225/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Hallucinogens)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Vasoconstrictor Agents)
RN  - 0 (Vasodilator Agents)
RN  - 169D1260KM (Nitroprusside)
RN  - 1WS297W6MV (Phenylephrine)
RN  - 7C0697DR9I (Atropine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - N9YNS0M02X (Acetylcholine)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Atropine/pharmacology
MH  - Blood Pressure/drug effects
MH  - Drug Interactions
MH  - Electrocardiography/drug effects
MH  - Hallucinogens/administration & dosage/*toxicity
MH  - Heart Diseases/*chemically induced/pathology/*physiopathology
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Injections, Intravenous
MH  - Male
MH  - Muscarinic Antagonists/pharmacology
MH  - Myocardium/pathology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*toxicity
MH  - Nitroprusside/pharmacology
MH  - Phenylephrine/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Substance-Related Disorders/*physiopathology
MH  - Telemetry
MH  - Vasoconstrictor Agents/pharmacology
MH  - Vasodilator Agents/pharmacology
EDAT- 2002/08/17 10:00
MHDA- 2002/09/19 10:01
CRDT- 2002/08/17 10:00
PHST- 2002/08/17 10:00 [pubmed]
PHST- 2002/09/19 10:01 [medline]
PHST- 2002/08/17 10:00 [entrez]
AID - 10.1124/jpet.302.3.898 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2002 Sep;302(3):898-907. doi: 10.1124/jpet.302.3.898.